Preview

Cancer Urology

Advanced search

Роль гормонотерапии у больных локализованным и местно-распространенным раком предстательной железы при использовании радикальных методов лечения

https://doi.org/10.17650/1726-9776-2005-1-2-54-58

About the Authors

В. Матвеев
ГУ РОНЦ им. Н.Н. Блохина РАМН
Russian Federation


М. Волкова
ГУ РОНЦ им. Н.Н. Блохина РАМН
Russian Federation


References

1. Давыдов М.И., Аксель Е.М. Злокачественные новообразования в России и странах СНГ в 2002 г. — М., 2004. — С. 110—167.

2. Prayer-Galetti T., Zattoni F., Capizzi A. et al. Disease free survival in patients with pathological C stage prostate cancer at radical reropubic prostatectomy submitted to adjuvant hormonal treatment //Eur.Urol. — 2000. — V. 38. — Аbstr. 48.

3. Messing E.M., Manola J., Sarosdy M. et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer //N.Engl.J.Med. — 1999. — V. 341, № 9. — Р. 1781—1788.

4. Soloway M.S., Sharifi R., Wajsman Z. et al. Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer // J. Urol. — 1995. — V. 154. — Р. 424—428.

5. Goldenberg S.L., Klotz L.H., Jewett M.A.S. et al. Randomized controlled study of neoadjuvant reversible androgen withdrawal therapy with cyproteron acetate in the surgical management of localized prostate cancer // J. Urol. — 1995. — V. 153. — Аbstr. 254A.

6. Van Poppel H., Ridder D.D., Elgamal A.A. et al. Neoadjuvant hormonal therapy before radical prostatectomy decreases the number of positive surgical margins in stage T2 prostate cancer: interim results of a prospective randomized study // J. Urol. — 1995. — V. 154. — P. 429—434.

7. Pollack A., Zagars G.K., Smith L.G. et al. Preliminary results of a randomized dose-escalation study camparing 70 Gy to 78 Gy for the treatment of prostate cancer // Int. J. Radiat. Oncol. Biol. Phys. — 1999. — V. 45. — P. 146.

8. Zelefsky M.J., Leibel S.A., Gaudin P.B. et al. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer // Int. J. Radiat. Oncol. Biol. Phys. — 1998. — V. 41. — P. 491—500.

9. Bolla M., Collette L., Blank L. еt al. Long-trem results with immediate androgen supression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomized trial // Lancet. — 2002. — V. 360, № 13. — P. 103—108.

10. Pilepich M., Winter K., Lawton C.A. et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinomalong-term results of phase III RTOG 85— 31 // Int. J. Radiat. Oncol. Biol. Phys. — 2005. — V. 61(5). — P. 1285—1290.

11. Granfors T., Modig H., Damber J.-E. et al. Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involvement: a prospective randomized study // J. Urol. — 1998. — V. 159(6). — P. 2030—2034.

12. Shipley W., Lu J.D., Pilepich M.V. et al. Effect of a short course of neoadjuvant hormonal therapy on the response to subsequent androgen suppression in prostate cancer patients with relapse after radiotherapy: a secondary analysis of the randomized protocol RTOG 86—10 // Int. J. Radiat. Oncol. Biol. Phys. — 2002. — V. 54 (5). — P. 1302—1310.

13. Hanks G.E., Pajak T.F., Porter A. et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92—02 // J. Clin. Oncol. — 2003. — V. 21 (21). — P. 3972—3978.

14. Holzbeierlein J.M., McLaughlin M.D., Thrasher J.B. Complications of androgen deprivation therapy for prostate cancer //Curr. Opin. Urol. — 2004. — V. 14 (3). — P. 177—183.

15. D’Amico A.V., Manola J., Loffredo M. et al. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial // JAMA. — 2004. — V. 292 (7). — P. 821—827.

16. Hanks G.E., Buzydlowski J., Sause W.T. et al. Ten-year outcomes for pathologic node-positive patients treated in RTOG 75—06. // Int. J. Radiat. Oncol. Biol. Phys. — 1998. — V. 40 (4). — P. 765—768.

17. Lawton C.A., Winter K., Byhardt R. et al. Androgen suppression plus radiation versus radiation alone for patients with D1 (pN+) adenocarcinoma of the prostate (results based on a national prospective randomized trial, RTOG 85-31). Radiation Therapy Oncology Group // Int. J. Radiat. Oncol. Biol. Phys. — 1997. — V. 38 (5). — P. 931—939.


Review

For citations:


 ,   . Cancer Urology. 2005;1(2):54-58. (In Russ.) https://doi.org/10.17650/1726-9776-2005-1-2-54-58

Views: 235


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1726-9776 (Print)
ISSN 1996-1812 (Online)
X